CClinicalTrials.gg
TerminatedNCT01173263Updated Mar 5, 2014

Effect of Bispectral Index (BIS) Titrated Propofol Sedation on Lower Esophageal Sphincter Pressures and Esophageal Function in Intensive Care Patients

An interventional study of BIS 70 maintained and BIS level 50 in Respiration, Artificial, sponsored by The Cleveland Clinic. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-03-05.

Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Prevention

Why this study was terminated
recruitment difficulties
Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Eligible patients will be allocated to receive propofol sedation titrated to 3 different Bispectral Index (BIS) levels in a random order. Primary hypothesis: Deepening propofol sedation - as determined by BIS - lowers esophageal pressure in critical care patients.

Read the detailed description

Patient will be selected from the ICU, based on the defined inclusion and exclusion criteria. Potential study subjects will be screened by the research fellow or the on-site study co-investigator. Eligible patients will be allocated to receive propofol sedation titrated to 3 different BIS levels in a random order. BIS XP monitors (Aspect Medical Systems, Norwood, MA, USA) will be used which are relatively resistant to EMG artifact; a BIS sensor will be position on forehead of the patient after the skin is degreased and gently abraded. Esophageal pressure monitoring will be performed by a catheter inserted from the nose to the esophagus and left there trough the study period.

If patients are on sedation they will be placed on propofol sedation for a washout period. Each patient will receive propofol sedation by continuous infusion titrated to a different levels of BIS in a randomized fashion according to a computer-generated random-number sequence;

  1. BIS levels of 70, will be targeted (Anxiolysis/high-frequency EEG activity, beta-augmentation);
  2. BIS levels of 50 will be targeted, (Low frequency EEG activity, theta-delta activity);
  3. BIS levels of 35 will be targeted (low frequency EEG activity). A propofol infusion will be titrated by the investigators to the designated BIS target according to randomization. Clinical personnel will not be blinded to the study, and if patient has clinically significant change in hemodynamic parameters study will be interrupted. Each BIS target level will be kept as constant as possible for at least one hour; thereafter, lower esophageal pressures will be recorded for 15 minutes using high resolution esophageal manometry. Studies will be done in supine position [Most ICU patients are now kept head-up.], and the manometric assembly will be positioned to record from the hypopharynx to the stomach with 4-6 of the sensors positioned in the stomach.

All patients will otherwise receive routine ICU care and medications without interruption of standard clinical care.

02

Conditions studied

  • Respiration, Artificial

Keywords

  • breathing machine
  • mechanical ventilator
03

In context

Lead sponsor

The Cleveland Clinic is the lead sponsor of 818 studies on the registry; 118 are open to participants now.

Of its 89 completed or terminated interventional studies of FDA-regulated products, 72 (81%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18-80 years of age
  • Written informed consent from relatives
  • Clinically stable
  • Mechanically ventilated \< 2days
  • Require sedation and expected to be given propofol

Exclusion criteria

Exclusion Criteria:

  • Recent injury or other pathologic condition of the esophagus
  • Major bronchopleural fistula
  • History of liver failure
  • History of renal failure
  • History of major neuromuscular disease
  • Multiple trauma
  • Upper motor nerve injury
  • Hypersensitivity to propofol
  • Recent gastrointestinal surgery
  • Patients with a diagnosed or suspected condition that may give false results in BIS monitoring.
  • Tracheostomized patients
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1 participant (actual)

Study arms

  • Active comparator
    BIS 70

    BIS levels of 70, will be targeted (Anxiolysis/high-frequency EEG activity, beta-augmentation);

    Other: BIS 70 maintained

  • Active comparator
    BIS 50

    BIS levels of 50 will be targeted, (Low frequency EEG activity, theta-delta activity)

    Other: BIS level 50

  • Active comparator
    BIS 35

    BIS levels of 35 will be targeted (low frequency EEG activity)

    Other: BIS 35

Interventions

  • OtherBIS 70 maintained

    Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 70.

    Also known as: sedation, propofol, BIS monitor, esophageal pressure, esophageal function

  • OtherBIS level 50

    Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 50.

    Also known as: sedation, propofol, BIS monitor, esophageal pressure, esophageal function

  • OtherBIS 35

    Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 35.

    Also known as: sedation, propofol, BIS monitor, esophageal pressure, esophageal function

06

What researchers measure

Primary outcomes

  1. Deepening propofol sedation - as determined by BIS - lowers esophageal pressure in critical care patients.

    Sedation will also be evaluated with the bispectral index of the electroencephalogram. BIS of the EEG data will be acquired with 4 BIS-sensor electrodes and a BIS XP monitor. The BIS will be recorded electronically at one-minute intervals. Heart rate, blood pressures (diastolic and systolic), respiratory rate, core temperature and oxygen saturation will be recorded every 5 minutes during the measurement period of the study.

    Time frame: for 15 minutes after assigned BIS level has been maintained for one hour, while in the ICU

Secondary outcomes

  1. Deepening propofol sedation - as measured by Sedation Agitation Scale, Richmond Agitation Scale Score, and Ramsay sedation scale - lowers esophageal pressure in critical care patients.

    The SAS uses a 1 to 7 point scale to make a determination of the patient's level of agitation and sedation from a rating of 7 dangerously agitated to a rating of 1 unarousable (Table 1). Clinical sedation assessments using SAS and RASS scales will be measured every 10 minutes through the study period.

    Time frame: every 10 minutes, while sedated in the ICU

  2. Modifying the target level of BIS titration affects upper esophageal pressures and esophageal peristalsis.

    Upper esophageal sphincter pressures, transient LES relaxations, and regurgitations will be evaluated by the GI team from recorded data from high resolution manometry.

    Time frame: for 15 minutes after assigned BIS level has been maintained for one hour, while in the ICU

  3. There is an association between ventilator associated pneumonia and baseline lower esophageal and barrier pressure.

    Patients will be followed for their stay in the hospital for occurrence of ventilator associated pneumonia.

    Time frame: daily, until hospital discharge

07

Study locations

1 site
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01173263
Lead sponsor
The Cleveland Clinic
Responsible party
Alparslan Turan (Principal Investigator, The Cleveland Clinic) — Principal investigator
First posted
Aug 2, 2010
Start date
Jul 2010
Primary completion
Mar 2011
Completion
Mar 2011
Last update
Mar 5, 2014

Study contacts

Alparslan Turan, M.D.
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion